Toboroz
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial
2025-521209-42-00· 4. fázis· Fondazione GONO G.I.· Forrás
Még nem toboroz
A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2
2025-521608-23-00· 2. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Toboroz
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
NCT07722546· 2. fázis· Biogen· Forrás
Toboroz
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782· 2. fázis· Verastem, Inc.· Forrás
Toboroz
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
2025-524001-33-00· 2. fázis· Immunovant Sciences GmbH· Forrás
Toboroz
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
NCT07596849· 3. fázis· argenx· Forrás
Toboroz
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· 3. fázis· Summit Therapeutics Inc.· Forrás
Toboroz
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
2025-521640-38-00· 3. fázis· Praxis Precision Medicines Inc.· Forrás
Toboroz
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
NCT07073079· AbbVie· Forrás
Fut, nem toboroz
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· 3. fázis· AbbVie· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· 2. fázis· Pfizer· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875· 3. fázis· AstraZeneca· Forrás
Toboroz
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
2023-507853-13-00· 2. fázis· Eli Lilly & Co.· Forrás
Toboroz
3TR-PARTNER-RA
2024-511470-79-00· 4. fázis· Queen Mary University Of London· Forrás
Toboroz
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910· 3. fázis· Takeda· Forrás
Toboroz
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604· 2. fázis· Immunovant Sciences GmbH· Forrás
Toboroz
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· 3. fázis· MedSIR· Forrás
Fut, nem toboroz
An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma
2024-512113-41-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
Steroid withdrawal in SLE
2024-518580-35-00· 4. fázis· Azienda Ospedaliero Universitaria Pisana· Forrás
Fut, nem toboroz
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319· 2. fázis· Sanofi· Forrás
Toboroz
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 Study
2023-506632-32-00· 3. fázis· Fondazione GONO G.I.· Forrás
Toboroz
Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy
NCT07268833· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Forrás
Meghívásos bevonás
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· 2. fázis· AbbVie· Forrás
Toboroz
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575· 3. fázis· Jazz Pharmaceuticals· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
2023-508359-38-00· 3. fázis· Amgen Inc.· Forrás
Fut, nem toboroz
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386· 4. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275· AbbVie· Forrás
Fut, nem toboroz
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183· 3. fázis· Pfizer· Forrás
Toboroz
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT06708429· San Raffaele University· Forrás
Toboroz
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
NCT05817903· 2. fázis· Consorzio Oncotech· Forrás
Fut, nem toboroz
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
NCT05578664· 2. fázis· Consorzio Oncotech· Forrás
Fut, nem toboroz
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446· 2. fázis· Pfizer· Forrás
Toboroz
Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study
2024-515681-14-00· 2. fázis· Fondazione IRCCS Istituto Nazionale Dei Tumori· Forrás
Fut, nem toboroz
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
NCT04564898· 1/2. fázis· Gruppo Oncologico del Nord-Ovest· Forrás
Fut, nem toboroz
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
NCT05312398· 2. fázis· University of Campania Luigi Vanvitelli· Forrás
Még nem toboroz
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
2024-519031-42-00· 3. fázis· Associazione Italiana Per Lo Studio Del Pancreas· Forrás
Toboroz
NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced rectal cancer. A multi-arm, multi-stage, intergroup (STAR-04/SICO-CR01/GISCAD/AIRO-GI) randomised clinical trial. The NeoAspMet trial
2024-519007-10-00· 2/3. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Még nem toboroz
ORGAN SPARING FOR LOCALLY ADVANCED RECTAL CANCER AFTER NEOADJUVANT TREATMENT FOLLOWED BY ELECTROCHEMOTHERAPY - LARC_ DEEP_CANCERS
2024-519050-37-00· 2. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Fut, nem toboroz
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318· 3. fázis· AbbVie· Forrás